Novartis pays $1.1B upfront (up to $1.5B total) for Myricx Bio, gaining its NMT inhibitor ADC payload platform and two preclinical oncology assets.
Novartis said Monday it will be spending $1.1 billion upfront to buy Myricx Bio, which has an ADC payload platform that could offer an edge …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push - Novartis (NYSE:NVS)
Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class
Novartis to acquire ADC developer in a deal worth up to $1.5B
London's Myricx Bio lands up to $1.5B Novartis exit after raising just $121M — TFN
Novartis acquires British start-up Myricx Bio
Correction to Novartis Article
Patent cliff fuels Novartis' $1.5bn swoop for London biotech
Novartis rileva Myricx Bio in un’operazione fino a 1,5 miliardi di dollari
Novartis: rileva gruppo biotecnologie Myricx Bio per 1,1 mld $
Aussie super funds hit the jackpot in $2b UK biotech deal
Novartis acquires Myricx Bio for up to $1.5B to boost its oncology pipeline with a novel next-gen ADC cancer platform. Read more.
Novartis will pay $1.1bn upfront and up to $400m in milestones for Myricx Bio, a UK firm developing a novel payload for…
The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC…
Novartis has agreed to acquire London biotech Myricx Bio for up to $1.5 billion, believing on its NMT inhibitor payload as a…
The Swiss pharma giant will pay $1.1 billion (CHF883 million) to acquire Myricx Bio, which is developing antibody-drug conjugates…
Novartis will pay up to $400 million in potential additional payments. "Novartis to Buy Myricx Bio for Up to $1.5 Billion," at…
